Cancer Care Conference Worldwide
Delivered – Virtually
January 28, 2025
Welcome to the Cancer Care Conference Worldwide. Hear from oncology experts and medical leaders as they discuss the latest breakthroughs in cancer treatment and patient care. Explore innovative therapies and technologies that are transforming the future of cancer care. Join us virtually on January 28, 2025, and gain unparalleled insight into cutting-edge developments in oncology.
What is the size of the oncology industry?
In 2023, the global oncology market was estimated to be in excess of $200 billion. The American Cancer Society claimed that there were nearly 2.0 million cancer patients in the U.S. alone at the end of 2023, up 28% since 2010. Globally, the International Agency for Research in Cancer believes that 18.1 million new cancer cases were reported in 2020. Most researchers forecast that revenues directed towards cancer care will surpass $500 billion annually by 2032.
Why is there a rising incidence of cancer?
The following are among the reasons that cancer is becoming more common:
- Demographics: The global population is both growing and aging, which naturally leads to more cancer cases as cancer risk increases with age.
- Lifestyle and Environmental Factors: Poor diet, alcohol consumption, tobacco use, physical inactivity, and obesity are key factors contributing to increasing cancer incidence. Air pollution remains a significant environmental risk factor.
- Detrimental Early Life Exposures: The early life “exposome,” which includes diet, lifestyle, weight, environmental exposures, and microbiome, has changed substantially in recent decades. Highly processed foods, sugary beverages, obesity, Type 2 diabetes, sedentary lifestyle, and alcohol consumption have all significantly increased since the 1950s.
- More Vigilant Detection: Enhanced screening programs and diagnostic technologies are detecting cancers earlier and more frequently, particularly in developed countries.
What are some new technologies designed to treat cancer?
The following are among the innovative methods and advancements in cancer treatment that are showing promise:
Personalized mRNA Cancer Vaccines: These vaccines are designed to target specific characteristics of a patient’s tumor.
Immunotherapy: Enhances the body’s immune system to recognize and attack cancer cells.
Targeted Therapies: Focus on precise molecular targets that regulate cancer cell growth and division.
CAR-T Cell Therapy: Uses genetically modified immune cells to fight cancer.
AI and Machine Learning: Being used to analyze medical imaging data for quicker and more accurate cancer detection. AI-based patient navigation tools are helping to improve cancer screening rates in underserved communities.
Genomic Medicine: Leverages genetic and genomic data to reveal novel ways of attacking cancer cells.
Next-Generation Cancer Organoids: 3D models of cancer cells that mimic tumor characteristics, allowing for personalized testing of treatments.
Nanoparticle-based Treatments: Being developed to target cancer cells more precisely.
Combination Therapies: Combines different treatment types, such as immunotherapy with chemotherapy, to improve outcomes.
Digital Biological Twins: Uses personalized tumor-derived organoids to test different treatment combinations and predict patient responses.
Where is money moving in the oncology industry?
A lot of money is moving around in the oncology industry. Below are some of the recent acquisitions and IPOs of cancer care companies:
- Johnson & Johnson acquired Ambrx Biopharma for $2 billion in January 2024, focusing on next-gen antibody-drug conjugates for cancer treatment.
- Merck & Co. acquired Harpoon Therapeutics for $680 million in January 2024, targeting novel T-cell engagers using the TriTAC® platform.
- Novartis agreed to acquire Mariana Oncology for $1 billion upfront plus $750 million in milestone payments in May 2024, focusing on radioligand therapies for cancer treatment.
- Bristol Myers Squibb completed the acquisition of Mirati Therapeutics in January 2024, strengthening its oncology portfolio.
- Boehringer Ingelheim acquired Nerio Therapeutics Inc. for $1.3 billion in July 2024, aiming to develop Neiro’s preclinical program for its immuno-oncology portfolio.
- CG Oncology went public in January 2024, raising $380 million. The company is developing cretostimogene grenadenorepvec for non-muscle invasive bladder cancer.
- ArriVent BioPharma went public in January 2024, raising $175 million for its oncology-focused pipeline.
- Boundless Bio launched its IPO in March 2024, raising $100 million to fund its extrachromosomal DNA programs for cancer treatment.
- Metagenomi went public in February 2024, raising $93.75 million to support its genome editing tools, which have applications in oncology.
What Will You Learn About the Presenting Companies?
Each management team will discuss their company’s existing and forthcoming product offerings. They will apprise listeners of their addressable markets and expectations for payor profiles. They will inform us of their research and development efforts, proprietary technologies and patent portfolios. They will tell us about their business models including the extent of their collaborations, licensing strategies, distribution channels, manufacturing strategies, milestones and exit strategies.
Please check back for the agenda of presenting companies. If you would like to nominate a company to present, please contact David Wanetick at dwanetick@davosinthedesert.us.
Registration is free for members of Davos in the Desert. The registration price for non-members is just $10. Registration is for one attendee. No refunds.
Register now to listen to presentations from industry leaders and innovators. Registration is free for members of Davos in the Desert. Non-members can register now for just $10. No refunds.
Secure your spot today and be part of shaping the future of semiconductors!